ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy por Laura Soumoy, Aline Genbauffe, Lena Mouchart, Alexandra Sperone, Anne Trelcat, Léa Mukeba-Harchies, Mathilde Wells, Bertrand Blankert, Ahmad Najem, Ghanem Ghanem, Sven Saussez, Fabrice Journe

Obter o texto integral